Biologics

Branded Benlysta DTC campaign ready to roll out

Marc Iskowitz October 26, 2011

New online and print DTC advertising targeting US patients with lupus will appear "within weeks," said executives from Human Genome Sciences. Can the campaign revive blockbuster fortunes for Benlysta?

GSK, HGS cleared to launch lupus drug with unrestricted label

Marc Iskowitz March 10, 2011

When co-marketers Human Genome Sciences and GlaxoSmithKline launch newly approved lupus drug Benlysta later this month, reps will be able to tout a broad label.

Generic Lovenox drags down Sanofi sales

Marc Iskowitz November 01, 2010

Sanofi-Aventis said US sales of anti-thrombotic Lovenox were cut nearly in half by the launch of generic competition, an indication hospitals are showing little hesitation in using the copycat version.

Amgen deploys up to 1,000 reps on Prolia approval

Ben Comer June 03, 2010

Amgen has deployed "500 to 1,000" reps in support of Prolia (denosumab), a biologic osteoporosis treatment that received FDA approval on June 1. The drug was approved in the European Union on May 28.

What's behind Humira's bullish forecast?

Marc Iskowitz May 04, 2010

A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.

FDA says competing biologic ads both misled

Ben Comer April 07, 2010

One is a sales aid, and one is a consumer brochure, but both ads -- for CSL Behring's Zemaira and for Talecris' Prolastin -- are false or misleading, FDA said in a pair of untitled letters.

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.